In this review:
Safety and clinical activity of atezolizumab combined with cobimetinib in metastatic melanoma
Safety and clinical activity of atezolizumab + cobimetinib + vemurafenib in BRAF-mutant metastatic melanoma
Efficacy of nivolumab plus ipilimumab combination in patients with advanced melanoma
Elevated baseline serum LDH does not preclude durable responses with pembrolizumab
Overall survival in the phase 3 CheckMate 037 trial
Outcomes in patients treated with ipilimumab after pembrolizumab in KEYNOTE-006
Results of COLUMBUS part 1: encorafenib plus binimetinib versus vemurafenib
Dabrafenib plus trametinib improves relapse-free survival versus standard of care
A phase 1 study of IMCgp100 in patients with advanced uveal melanoma
Intratumoural SD 101 in combination with pembrolizumab in patients with metastatic melanoma
Please login below to download this issue (PDF)